Comparison of VerifyNow, thromboelastography, and PL-12 in patients with minor ischemic stroke or transient ischemic attack

Lin Ma[^1^,^2^,^3^,*], Weiqi Chen[^1^,^2^,^3^,*], Yuesong Pan[^1^,^2^,^3^], Hongyi Yan[^1^,^2^,^3^], Hao Li[^1^,^2^,^3^], Xia Meng[^1^,^2^,^3^], Yongjun Wang[^1^,^2^,^3^], Yilong Wang[^1^,^2^,^3^]

[^1^]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China  
[^2^]China National Clinical Research Centre for Neurological Diseases (NCRC-ND), Beijing, China  
[^3^]Advanced Innovation Centre for Human Brain Projection, Capital Medical University, Beijing, China  
*Equal contribution

Correspondence to: Yilong Wang; email: yilongwang@ccmu.edu.cn  
Keywords: high on-treatment platelet reactivity, platelet function, ischemic stroke, transient ischemic attack, antiplatelet therapy

Received: July 22, 2020  Accepted: September 29, 2020  Published: March 03, 2021

Copyright: © 2021 Ma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

High on-treatment platelet reactivity (HOPR) is associated with stroke recurrence. It is important to find a reliable method to assess HOPR. We aimed to compare the correlations between VerifyNow™ system, thromboelastography (TEG), and Aggrestar platelet function analyzer (PL-12) on platelet activity in patients with minor ischemic stroke or transient ischemic attack (TIA) after dual antiplatelet therapy for 7 days. About 276 patients were included. Spearman’s correlation coefficient and the kappa coefficient were adopted to evaluate associations among the three test methods. An obvious correlation between VerifyNow and TEG on HOPR-ADP (r=0.64, p<0.001) was found. The correlations of HOPR-ADP between PL-12 and the other two platelet function analyzers were moderate (PL-12 versus VerifyNow, r=0.47, p<0.001; PL-12 versus TEG, r=0.25, p<0.001). The correlations of HOPR-AA were limited among these three platelet function analyzers (VerifyNow versus TEG, r=0.09, p=0.14; VerifyNow versus PL-12, r=0.15, p=0.01; PL-12 versus TEG, r=0.10, p=0.09). Correlations among different platelet function analyzers were varied. VerifyNow and TEG were more correlative than PL-12 on HOPR-ADP. The consistence of HOPR-AA was limited among VerifyNow, TEG and PL-12. The proportion of stroke recurrence and composite events in patients with HOPR-ADP assessing by PL-12 was higher than VerifyNow and TEG.

INTRODUCTION

Large clinical trials have shown that the combination of clopidogrel and aspirin reduced the risk of stroke recurrence [1, 2]. However, some patients still experience recurrent ischemic events with dual antiplatelet therapy. High on-treatment platelet reactivity (HOPR) refers to the limited degree of the inhibition of platelet aggregation compared with the inhibition expected using antiplatelet therapy [3]. HOPR is considered as one of the most important reasons of recurrent ischemic events with dual antiplatelet therapy [4, 5]. In this study, we used “High on-treatment platelet reactivity of AA” (HOPR-AA) and “High on-treatment platelet reactivity of ADP” (HOPR-ADP) to describe HOPR assessing by aspirin and P2Y12-specific cartridges respectively. It is valuable to assess HOPR in clinical practice [5–10].

Plenty of laboratory assays could be used to examine platelet function in vitro. Light transmission aggregometry (LTA) is a standard method for evaluating platelet function, which is based on the change of turbidity in light transmission. LTA is a...
flexible and time-consuming method. Its completion requires large blood volumes and experienced laboratory technicians [4, 7]. Quicker and more user-friendly analyzers are needed. VerifyNow™ system (VerifyNow) is a point-of-care platelet function analyzer based on light transmission, which is the same mechanism with LTA [8]. Previous studies have shown that VerifyNow got an obvious correlation with LTA [9, 11]. We consider VerifyNow as a standard analyzer in our study. Thromboelastography (TEG) is designed to measure clot formation, clot strength, and clot degradation, and it is one of the most common whole-blood platelet function tests used in clinical practice. However, TEG is subject to a unique set of pre-analytic and analytic variables that influence the reliability and reproducibility of the test [10]. Aggrestar platelet function analyzer (PL-12) is a new automated analyzer based on the platelet count drop method. It counts platelet twice before the addition of an agonist in whole blood samples [12]. However, the coagulation function, mean platelet volume, and number of platelets before the measurements might affect the interpretation of platelet reactivity assessed by PL-12.

Owing to the different detection principles, different methods have different advantages. Little research has been published about the agreement among VerifyNow, TEG, and PL-12 in patients with minor stroke or transient ischemic attack (TIA). Therefore, we aimed to compare TEG and PL-12 with VerifyNow to evaluate their agreement in assessing HOPR- AA/ADP in minor ischemic stroke or TIA patients, and to compare the correlation between HOPR assessed by platelet function analyzers and clinical events (i.e., stroke, TIA, myocardial infarction, or vascular death).

RESULTS

Baseline characteristics

Among 675 patients enrolled in the PRINCE trial, 276 patients were included in this analysis. The baseline characteristics of patients included and excluded in the subgroup analysis were shown in Supplementary Table 1. The median age of the participants included in the subgroup analysis was 61 years, and 28.9% of them were women. The index event was a minor stroke in 231 patients (83.7%) and a TIA in 45 patients (16.3%). The baseline laboratory characteristics were also compared between these two groups (Supplementary Table 1).

Platelet function results

About 44 patients (15.94%) were detected to have HOPR-ADP via VerifyNow. TEG showed 39 patients (14.13%) with HOPR-ADP. About 14 patients (5.07) were detected to have HOPR-ADP by PL-12. Twenty-five patients (9.10%) showed HOPR-AA via VerifyNow. A number of 36 patients (13.04%) showed HOPR-AA via TEG, and 8 patients (2.90%) was found HOPR-AA in the PL-12.

Comparison of different tests in assessing HOPR-ADP

The correlation between VerifyNow and TEG is highest in our study (r=0.64, p<0.001; Table 1). The kappa value is 0.31 (Table 2). The receiver operating characteristic (ROC) curve analysis suggests that 49.2% should be the cutoff value for PL-12, with 98% sensitivity and 16% specificity (Supplementary Table 2). A limited correlation was found between VerifyNow and TEG (r=0.09, p=0.14; Table 1), and the kappa value was 0.03 (Table 2). The ROC analysis suggested that the cutoff value of ADPI should be 58.8% for TEG, with a sensitivity of 68.1% and a specificity of 81.8% (Supplementary Table 2). The correlation between VerifyNow and PL-12 was also obvious (r=0.47, p<0.001; Table 1). The kappa value was 0.22 (Table 2). The cutoff value of MARADP should be 28.6% with 95.5% sensitivity and 67.7% specificity (Supplementary Table 2). TEG and PL-12 showed a moderate correlation (r=0.25, p<0.001; Table 1). The kappa value was 0.08 (Table 3). The comparison of these three methods is shown in Figure 1.

Comparison of different tests in assessing HOPR-AA

HOPR-AA was limited among VerifyNow, TEG and PL-12. VerifyNow and PL-12 got a weak correlation (r=0.15, p=0.01; Table 4), and the kappa value was 0.14 (Table 2). The ROC analysis suggested that 49.2% should be the cutoff value for PL-12, with 98% sensitivity and 16% specificity (Supplementary Table 2). A limited correlation was found between VerifyNow and TEG (r=0.09, p=0.14; Table 4), and the kappa value was 0.03 (Table 2). The ROC analysis suggested that the cutoff value of TEG-AA inhibition should be 97.4% for PL-12, with 76% sensitivity and 56% specificity (Supplementary Table 2). The correlation between PL-12 and TEG was also limited (r=0.10, p=0.09; Table 4), and the kappa value was 0.05 (Table 3). The comparison of these three methods is shown in Figure 1.

Relationships between HOPR detected by platelet function analyzers and clinical outcomes

Table 5 showed the relationship between HOPR and clinical outcomes. The proportions of stroke recurrence and composite events in patients with HOPR-ADP assessing by PL-12 were higher than VerifyNow and TEG. At 3 months, 2 patients (14.3%) who were found...
Table 1. Correlation between VerifyNow, thromboelastography (TEG), and PL-12 for HOPR-ADP.

| Methods          | PL-12 r | p Value  | TEG r   | p Value |
|------------------|---------|----------|---------|---------|
| VerifyNow        | 0.47    | < 0.001  | -0.64   | < 0.001 |
| TEG              | -0.25   | < 0.001  |         |         |

Because HOPR-ADP in the TEG test was defined as ADP inhibition < 30%, which was contrary to the trends of other tests, the r value was negative.

Table 2. Comparison between VerifyNow, thromboelastography (TEG), and PL-12 in identifying HOPR.

| Method (agonist) | Definition of HOPR | Patients with HOPR n (%) | Kappa |
|------------------|--------------------|--------------------------|-------|
| VerifyNow (ADP)  | PRU > 208          | 44 (15.9)                | - (reference method) |
| TEG (ADP)        | ADPI < 30%         | 39 (14.1)                | 0.31  |
| PL-12 (ADP)      | MAR_{ADP} ≥ 55%    | 14 (5.1)                 | 0.22  |
| VerifyNow (AA)   | ARU ≥ 550          | 25 (9.1)                 | - (reference method) |
| TEG (AA)         | AAI < 50%          | 36 (13.0)                | 0.03  |
| PL-12 (AA)       | MAR_{AA} > 50%     | 8 (2.9)                  | 0.14  |

HOPR, high on-treatment platelet reactivity; AA, arachidonic acid; ARU, aspirin reaction units; PRU, P2Y12 reaction units; AAI, arachidonic acid inhibition; ADPI, ADP inhibition; MAR_{AA}, maximal platelet aggregation ratio of arachidonic acid-stimulated platelets; MAR_{ADP}, maximal platelet aggregation ratio of ADP-stimulated platelets.

Table 3. Comparison between thromboelastography (TEG) and PL-12 in identifying HOPR.

| Method (agonist) | Definition of HOPR | Patients with HOPR n (%) | Kappa |
|------------------|--------------------|--------------------------|-------|
| TEG (ADP)        | ADPI < 30%         | 39 (14.1)                | 0.08  |
| PL-12 (ADP)      | MAR_{ADP} ≥ 55%    | 14 (5.1)                 | 0.05  |
| TEG (AA)         | AAI < 50%          | 36 (13.0)                |       |
| PL-12 (AA)       | MAR_{AA} > 50%     | 8 (2.9)                  |       |

HOPR, high on-treatment platelet reactivity; AA, arachidonic acid; AAI, arachidonic acid inhibition; ADPI, ADP inhibition; MAR_{AA}, maximal platelet aggregation ratio of arachidonic acid-stimulated platelets; MAR_{ADP}, maximal platelet aggregation ratio of ADP-stimulated platelets.

HOPR-ADP by VerifyNow got stroke recurrence and composite events, but no significant correlation was found (p=0.26). Compared with VerifyNow, TEG/PL-12 had lower proportion of stroke among patients with HOPA-ADP (VerifyNow: 13.6%, p=0.05; TEG: 7.7%, p=0.83). Two patients (25.00%) with HOPR-AA assessed by PL-12 were found stroke recurrence and composite events, and 2 (8.0%) were found in VerifyNow. TEG found that three patients (8.3%) with HOPR-AA got recurrent stroke.

**DISCUSSION**

We compared three platelet function assays (VerifyNow, TEG and PL-12) for assessing HOPR-AA/ADP in patients with minor ischemic stroke or TIA. Both TEG and PL-12 got an obvious correlation with VerifyNow in monitoring HOPR-ADP. However, the correlation of HOPR-ADP between PL-12 and TEG is moderate. VerifyNow got little correlation with TEG and PL-12. The correlation between PL-12 and TEG is also limited.

Previous studies evaluating the platelet function found a very low prevalence of HOPR-AA, and such results may likely be due to noncompliance [1, 13]. Our results were in agreement with these observations. The small numbers of HOPR-AA made this comparison more uncertain [14–18]. Large cohort studies were needed to confirm the correlation of HOPR-AA between these
three platelet function tests. In our study, the prevalence of HOPR-ADP was higher than previous study. Madsen et al. compared VerifyNow and TEG with LTA for assessing the long-term effects of concomitant aspirin and clopidogrel therapy on platelet inhibition in patients treated with elective PCI [5]. A number of 33 patients completed tests at baseline. Four patients were found HOPR-AA in the LTA test, and both TEG and VerifyNow found only one patient who got HOPR-AA. The results of our study might be attributed to the fact that HOPR-ADP were more popular in Chinese population [19]. And the sample size of our analysis was larger than previous studies. Further, the sample size of our analysis was larger than that of previous negative studies.

The consistence between platelet function analyzers in previous studies was varied. Some studies reported that VerifyNow and TEG were moderate or non-correlative in assessing HOPR-ADP [1, 13, 15], whereas other studies found obvious correlations. Guan et al. demonstrated an obvious correlation between PL-11 with VerifyNow and TEG in health individuals [12].

Correlations of HOPR-ADP between methods were obvious (PL-11 versus VerifyNow, r=0.83, p<0.01; PL-11 versus TEG, r=0.70, p<0.001). In our study, we assessed HOPR-AA and HOPR-ADP after dual antiplatelet therapy for 7 days. Dual antiplatelet therapy was more effective at 7 days than baseline, and the result of platelet function was more reliable.

Previous studies have investigated HOPR was associated with stroke recurrence. However, few studies compared the correlation between HOPR assessed by different platelet function analyzers and clinical outcomes. In our studies, we found the proportion of stroke recurrence was highest in patients with HOPR monitored by PL-12. It might suggested that PL-12 was more reliable to predict stroke recurrence in clinical practice.

Difference analyzers have difference advantage and disadvantage. Verify Now is a commonly used point-of-care platelet function test. It uses optical turbidimetric technology to evaluate the platelet function [20]. However, erythrocytes may influence the signal during

Figure 1. Comparison of platelet function analyzers to assessing HOPR-ADP/AA. (A) The comparison between VerifyNow and TEG in assessing HOPR-ADP. (B) The comparison between VerifyNow and PL-12 in assessing HOPR-ADP. (C) The comparison between TEG and PL-12 in assessing HOPR-ADP. (D) The comparison between VerifyNow and TEG in assessing HOPR-AA. (E) The comparison between VerifyNow and PL-12 in assessing HOPR-AA. (F) The comparison between TEG and PL-12 in assessing HOPR-AA.
In conclusion, compared to VerifyNow, TEG showed a better correlation than PL-12 in assessing HOPR-AA. PL-12 and TEG got a moderate correlation in assessing HOPR-AA. The prevalence of HOPR-AA was low, and the correlations between VerifyNow, TEG and PL-12 were limited. Compared with VerifyNow/TEG, the proportion of stroke recurrence in HOPR-AA assessed by PL-12 was higher.

**MATERIALS AND METHODS**

**Overview of the PRINCE trial and the platelet function test substudy**

The PRINCE (Effect of Ticagrelor with Clopidogrel on High On-treatment Platelet Reactivity in Acute Stroke or Transient Ischemic Attack) trial was...
designed as a prospective, multicenter, randomized, open-label, active-controlled, and blind-endpoint, phase IIb trial [1, 22]. The details of the design, rationale, and major results have been previously described. The data of the present subgroup analysis were derived from the prespecified platelet function test substudy of the PRINCE trial. The substudy involved three visits: 2 hours after taking the first agents, 24 hours after taking the first agents, and day 7 + 2 days. The blood samples of this subgroup were collected at 2–4 hours after taking the investigational drugs. Patients without all three platelet function tests at 7 days were excluded from the present analysis. Of the 26 centers included in the PRINCE trial, a total of 276 participants in 11 centers voluntarily participated in this analysis, in which the platelet reactivity was evaluated by VerifyNow, TEG, and PL-12 (Figure 2).

Standard protocol approvals, registrations, and patient consents

The PRINCE trial was registered in ClinicalTrials.gov (NCT02506140) and approved by the ethics committee of Beijing Tiantan Hospital and all centers. Written informed consent was obtained from all participants or their legal representatives before being entered into the study.

Blood sampling

Six tubes of peripheral venous blood samples were collected at 2–4 hours after taking the investigational drugs. The first 2 mL of blood was discarded. A 3.2% sodium citrate tube (Greiner Bio-One Vacuette North America Inc., Monroe, NC) was used for VerifyNow analysis. A heparin tube (Becton-Dickinson, Franklin Lakes, NJ) was used for the TEG test, and two 3.2% sodium citrate tubes (Becton-Dickinson, Franklin Lakes, NJ) were used for the TEG and PL-12 tests, respectively. The tubes were gently inverted 10 times to ensure complete mixing of the blood sample with the anticoagulant. Blood samples were kept at 27°C before testing. The whole procedure needed to be performed within 2 hours after sampling.

Platelet function tests

VerifyNow analysis

The VerifyNow system (Accumetrics, San Diego, CA, USA) is a point-of-care test based on the optical change

---

Figure 2. Flow diagram for the enrollment process of this study from the PRINCE trial.
in whole blood samples to identifying platelet function [4, 23]. The whole blood sample was decanted into the reaction cartridge after being inserted into the apparatus. We used the aspirin- and P2Y12-specific cartridges to identify platelet dysfunction caused by aspirin and clopidogrel, respectively. Arachidonic acid (AA) was the platelet activation agent used in the aspirin test. If aspirin was not effective, cyclooxygenase-1 was activated to transform AA to thromboxane A2, leading to platelet aggregation. The degree of aggregation is reported in aspirin reaction units (ARU). A value ≥ 550 ARU indicates HOPR-AA [24, 25]. In the P2Y12-specific cartridge, the P2Y12 receptor was specially suppressed by ADP, and the changes in light transmission was measured as P2Y12 reaction units (PRU). A value > 208 PRU was defined as HOPR-ADP [23, 26, 27].

**TEG platelet mapping™ assay**

TEG (Heamoscope Corporation, Niles, IL) is a noninvasive assay that tests platelet function [28]. Different agonists and anticoagulant venous blood samples were placed into a special cup. The concentration of the activator added to the whole blood was 1 mmol/L AA or 2 mmol/L ADP. A special cup containing venous blood was rotated at 4° 45', with each rotation lasting 10 s. The fibrin-platelet complex cohered to the cup, and the rotary torque of the cup was transferred to the pin immersed in the blood sample. The rotation of the pin was converted to electrical signals by electromechanical sensors, which were monitored by a computer. Maximum amplitude (MA) directly reflects the maximal clot strength that facilitates the formation of the cross-linked fibrin clot. The MA of the cyclooxygenase-1 pathway and P2Y12 was measured as MA_{AA} and MA_{ADP}, respectively. We defined a<50% and<30% inhibition of AA- and ADP-induced clot formation (i.e., TEG-AA inhibition, TEG-ADP inhibition [ADPI]) as HOPR-AA and HOPR-ADP, respectively [6, 29]. AA/ADPI was calculated using the following formula:

\[
\text{AA or ADP Inhibition} = 100 - 100 \times \left( \frac{\text{MA}_{\text{AA or ADP}} - \text{MA}_{\text{fibrin}}}{\text{MA}_{\text{thromb}} - \text{MA}_{\text{fibrin}}} \right)
\]

**PL-12 analysis**

The PL-12 platelet function analyzer (SINOWA Medical Science and Technology Co., Nanjing, China) is a new point-of-care platelet function analysis tool based on the SPCM [12]. SPCM was used to determine platelet parameters such as number and volume, and to calculate the platelet aggregation ratio by using the change of platelet number before and after the agent was induced, thus allowing to dynamically evaluate the platelet function. The blood sample was gently mixed in a constant temperature for 10 min. Thereafter, 500 mL citrated blood sample was transferred to the detecting position. The whole analysis procedure was performed automatically. When the aggregated platelets were too large to be counted, they were dropped from the single platelet counting. PL-12 counted several times until the lowest level was detected. A value of MAR_{AA} > 50% was defined as HOPR-AA, and a value of MAR_{ADP} ≥ 55% was defined as HOPR-ADP. The maximal platelet aggregation ratio (MAR) was calculated using the following formula:

\[
\text{Percentage of MAR (\%MAR)} = \left\{ \frac{100 - \left[ \left( \frac{\text{1st platelet count} + 2\text{nd platelet count}}{2} \right) \right]}{\text{lowest platelet count}} \right\} \times 100\%
\]

**Outcomes assessment**

The study’s primary outcome was the proportion of patients with HOPR at 7 days. Secondary outcomes were clinical outcomes at 90 ± 7 days. The clinical outcomes included ischemic stroke and composite clinical vascular events (ischemic/hemorrhagic stroke, TIA, myocardial infarction, or vascular death) at 90 ± 7 days.

**Statistical analysis**

Continuous variables are presented as means with standard deviations or medians with interquartile ranges, and categorical variables are presented as percentages. The baseline characteristics were compared between the included group and the excluded group, using Student’s t-test for continuous variables, and the \( \chi^2 \) test for categorical variables. Kappa analysis was used to assess the classification consistency of HOPR among the three methods. Pearson’s correlation coefficient was adopted to evaluate the relationships among methods when the data were in a normal distribution. The \( \chi^2 \) test was used to compared HOPR and clinical outcomes. Two-sided p values<0.05 were considered statistically significant. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA). Anonymized data are available to researchers on request for reproducing the results or replicating the procedures by contacting the corresponding author.

**AUTHOR CONTRIBUTIONS**

Dr Yilong Wang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and
CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This study was supported by grants from the National Natural Science Foundation of China (81901177, 81825007, and 81971091); Beijing Outstanding Young Scientist Program (no. BJJWZYJH01201910025030); the “Thirteenth-Five” Key Development and Research Plan by the Ministry of Science and Technology of the People’s Republic of China (no. 2017YFC1307900); Beijing Hospitals Authority Youth Programme (QML20190501); Beijing Science and Technology Plan by Beijing Municipal Science and Technology Commission (no. D171100003017001); Beijing TianTan Hospital, Capital Medical University (2018-YQN-1, 2020MP01); Beijing Excellent Talents Training and Supporting - Top Youth Team by Beijing Municipal Science and Technology Commission (no. 2016000021223TD03); Youth Beijing Scholar Program; and Beijing Talent Project - Class A: Innovation and Development (no. 2018A12).

REFERENCES

1. Wang Y, Lin Y, Meng X, Chen W, Chen G, Wang Z, Wu J, Wang D, Li J, Cao Y, Xu Y, Zhang G, Li X, et al, and PRINCE Protocol Steering Group. Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: rationale and design. Int J Stroke. 2017; 12:321–25. https://doi.org/10.1177/1747493017694390 PMID:28381198

2. Papapanagiotou A, Daskalakis G, Siasos G, Gargalionis A, Papavassiliou AG. The role of platelets in cardiovascular disease: molecular mechanisms. Curr Pharm Des. 2016; 22:4493–505. https://doi.org/10.2174/13816122822666160607064118 PMID:27281334

3. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, et al, and Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013; 62:2261–73. https://doi.org/10.1016/j.jacc.2013.07.101 PMID:24076493

4. Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. Platelets. 2013; 24:352–61. https://doi.org/10.3109/09537104.2012.700969 PMID:22757746

5. Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendrigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem. 2010; 56:839–47. https://doi.org/10.1373/clinchem.2009.137471 PMID:20224050

6. Corliss BM, Polifka AJ, Harris NS, Hoh BL, Fox WC. Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: comparing results of the VerifyNow P2Y12 assay to thrombelastography with platelet mapping. J Neurosurg. 2018; 129:1160–65. https://doi.org/10.3171/2017.6.JNS17535 PMID:29271717

7. Althaus K, Zieger B, Bakhchoul T, Jurk K, and THROMKID-Plus Studiengruppe der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) und der Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Standardization of light transmission aggregometry for diagnosis of platelet disorders: an inter-laboratory external quality assessment. Thromb Haemost. 2019; 119:1154–61. https://doi.org/10.1055/s-0039-1688791 PMID:31154663

8. van Werkum JW, Harmsze AM, Eilsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets. 2008; 19:479–88. https://doi.org/10.1080/09537100802317918 PMID:18979359

9. Lv HH, Wu S, Liu X, Yang XL, Xu JF, Guan YT, Dong Q, Zheng SL, Jiang JM, Li SX, Luo Z, Li L, An LX, Han Y. Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China. Neurol Sci. 2016; 37:277–82.
10. Karon BS. Why is everyone so excited about thromboelastography (TEG)? Clin Chim Acta. 2014; 436:143–48. https://doi.org/10.1016/j.cca.2014.05.013 PMID: 24880040

11. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost. 2010; 103:1245–53. https://doi.org/10.1160/TH09-08-0527 PMID: 20352155

12. Guan J, Cong Y, Ren J, Zhu Y, Li L, Deng X, Bai J. Comparison between a new platelet count drop method PL-11, light transmission aggregometry, VerifyNow aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals. Platelets. 2015; 26:25–30. https://doi.org/10.3109/09537104.2013.865835 PMID: 24433273

13. Connelly CR, Yonge JD, McCully SP, Hart KD, Hilliard TC, Lape DE, Watson JJ, Rick B, Houser B, Deloughery TG, Schreiber MA, Kiraly LN. Assessment of three point-of-care platelet function assays in adult trauma patients. J Surg Res. 2017; 212:260–69. https://doi.org/10.1016/j.jss.2017.01.008 PMID: 28550916

14. Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, Domanski M. Frequency of aspirin resistance in a community hospital. Am J Cardiol. 2006; 98:577–79. https://doi.org/10.1016/j.amjcard.2006.03.029 PMID: 16923439

15. Meen O, Brosstad F, Khiabani H, Gjertsen E, Lauritsen ME, Pedersen TM, Bjørnsen S, Schjelderup NM, Ameln W, Ng EC, Wettergreen M, Siddique SP, Eriksen G. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest. 2008; 68:185–91. https://doi.org/10.1080/003665510701601673 PMID: 17934975

16. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost. 2006; 4:813–19. https://doi.org/10.1111/j.1538-7836.2006.01867.x PMID: 16634751

17. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005; 95:973–75. https://doi.org/10.1016/j.amjcard.2004.12.038 PMID: 15820166

18. Gurbel PA, Bleden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Geisheft T, Chaganti SK, Etherington A, Tantry US. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007; 115:3156–64. https://doi.org/10.1161/CIRCULATIONAHA.106.675587 PMID: 17562955

19. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, Wang Y, and CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016; 316:70–78. https://doi.org/10.1001/jama.2016.8662 PMID: 27348249

20. Saw J, Madsen EH, Chan S, Maurer-Spurej E. The ELAPSE (evaluation of long-term clopidogrel antiplatelet and systemic anti-inflammatory effects) study. J Am Coll Cardiol. 2008; 52:1826–33. https://doi.org/10.1016/j.jacc.2008.08.047 PMID: 19038679

21. Bal Dit Sollier C, BERGE N, BOVAL D, DUBAR M, DROUET L. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost. 2010; 104:571–81. https://doi.org/10.1160/TH09-11-0803 PMID: 20664906

22. Wang Y, Johnston SC, Bath PM, Grotta JC, Pan Y, Amarenco P, Wang Y, Simon T, Kim JS, Jeng JS, Liu L, Lin Y, Wong KS, et al. Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. BMJ. 2019; 364:l895. https://doi.org/10.1136/bmj.l895 PMID: 30819687

23. Kim YG, Suh JW, Sibbing D, Kastrati A, Ko YG, Jang Y, Cho YS, Youn TJ, Chae IH, Choi DJ, Kim HS. A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: a systematic review and meta-analysis. Am Heart J. 2017; 188:53–64. https://doi.org/10.1016/j.ahj.2017.03.006 PMID: 28577681

24. Wang CW, Su LL, Hua QJ, He Y, Fan YN, Xi TT, Yuan B, Liu YX, Ji SB. Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. Brain Res Bull. 2018; 142:176–82. https://doi.org/10.1016/j.brainresbull.2018.07.004 PMID: 30016728
25. Furtado RH, Giugliano RP, Dalcoquio TF, Arantes FB, Barbosa CJ, Genestreti PR, Franci A, Menezes FR, Nakashima CA, Scanavini Filho MA, Ferrari AG, Salsoso R, Baracioli LM, Nicolau JC. Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. J Thromb Thrombolysis. 2019; 48:217–24. https://doi.org/10.1007/s11239-019-01830-z PMID:30879169

26. Jimenez Diaz VA, Tello-Montoliu A, Moreno R, Cruz Gonzalez I, Baz Alonso JA, Romaguera R, Molina Navarro E, Juan Salvadores P, Paredes Galan E, De Miguel Castro A, Bastos Fernandez G, Ortiz Saez A, Fernandez Barbeira S, et al. Assessment of platelet REACtivity after transcatheter aortic valve replacement: the REAC-TAVI trial. JACC Cardiovasc Interv. 2019; 12:22–32. https://doi.org/10.1016/j.jcin.2018.10.005 PMID:30621974

27. Dehghani P, Lavoie A, Lavi S, Crawford JJ, Harenberg S, Zimmermann RH, Booker J, Kelly S, Cantor WJ, Mehta SR, Bagai A, Goodman SG, Cheema AN. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. Am Heart J. 2017; 192:105–12. https://doi.org/10.1016/j.ahj.2017.07.013 PMID:28938956

28. Othman M, Kaur H. Thromboelastography (TEG). Methods Mol Biol. 2017; 1646:533–43. https://doi.org/10.1007/978-1-4939-7196-1_39 PMID:28804853

29. Yao Y, Zhang JH, Tang XF, He C, Ma YL, Xu JJ, Song Y, Liu R, Meng XM, Song L, Wang M, Gao RL, Yuan JQ. Head to head comparison of two point-of-care platelet function tests used for assessment of on-clopidogrel platelet reactivity in Chinese acute myocardial infarction patients undergoing percutaneous coronary intervention. Chin Med J (Engl). 2016; 129:2269–74. https://doi.org/10.4103/0366-6999.190664 PMID:27647183
**SUPPLEMENTARY MATERIALS**

**Supplementary Tables**

**Supplementary Table 1.** Baseline characteristics of patients with HOPR monitored by verifynow, TEG and PL-12 at 7 days and patients without all these tests.

| Characteristic                          | Patients with HOPR monitored by verifynow, TEG and PL-12 (n = 276) | Patients without HOPR monitored by verifynow, TEG and PL-12 (n = 399) | p Value |
|----------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|---------|
| Age (years)                            | 61.2 ± 8.8                                                        | 61.2 ± 8.7                                                          | 0.27    |
| Median                                 | 61.0                                                              | 62.0                                                               |         |
| Interquartile range                    | 55.5–67.0                                                         | 54.0–67.0                                                          |         |
| Female sex, no. (%)                    | 195 (28.89)                                                       | 299 (44.30)                                                        | 0.22    |
| Medical history, no. (%)               |                                                                  |                                                                    |         |
| Hypertension                           | 166 (24.59)                                                       | 245 (36.30)                                                        | 0.74    |
| Dyslipidemia                           | 21 (3.11)                                                         | 20 (2.96)                                                          | 0.17    |
| Diabetes mellitus                      | 60 (8.89)                                                         | 104 (15.41)                                                        | 0.20    |
| Ischemic stroke                        | 50 (7.41)                                                         | 71 (10.52)                                                         | 0.91    |
| TIA                                    | 9 (1.33)                                                          | 9 (1.33)                                                           | 0.43    |
| Coronary artery disease                | 7 (1.04)                                                          | 44 (6.52)                                                          | < 0.001 |
| Smoking status, no. (%)                |                                                                  |                                                                    | 0.06    |
| Nonsmoker                              | 131 (19.41)                                                       | 174 (25.78)                                                        |         |
| Current smoker                         | 118 (17.48)                                                       | 201 (29.78)                                                        |         |
| Ex-smoker                              | 27 (4.00)                                                         | 24 (3.56)                                                          |         |
| Drug use before randomization — no. (%)|                                                                  |                                                                    |         |
| Statin                                  | 37 (5.48)                                                         | 29 (4.30)                                                          | 0.01    |
| Aspirin                                 | 68 (10.07)                                                        | 78 (11.56)                                                         | 0.11    |
| Clopidogrel                             | 9 (1.33)                                                          | 6 (0.89)                                                           | 0.12    |
| Qualifying event, no. (%)              |                                                                  |                                                                    | 0.93    |
| Minor stroke                           | 231 (34.22)                                                       | 333 (49.33)                                                        |         |
| TIA                                    | 45 (6.67)                                                         | 66 (9.78)                                                          |         |
| Platelet count (10^9/L)                | 217.5 ± 60.1                                                      | 220.0 ± 58.8                                                       | 0.60    |
| Median                                 | 210.0                                                             | 216                                                                |         |
| Interquartile range                    | 177.0–252.0                                                      | 178.0–255.0                                                       |         |
| APTT (s)                               | 32.7 ± 5.4                                                        | 32.5 ± 5.4                                                         | 0.69    |
| Median                                 | 33.1                                                              | 32.6                                                               |         |
| Interquartile range                    | 29.2–36.4                                                        | 29.2–35.7                                                          |         |
| VerifyNow                               |                                                                  |                                                                    |         |
| PRU                                    | 259.8 ± 55.6                                                      | 246.1 ± 58.7                                                       | 0.002   |
| Median                                 | 260.0                                                             | 243.0                                                               |         |
| Interquartile range                    | 224.0–296.0                                                      | 210.0–277.0                                                       |         |
| ARU                                    | 584.4 ± 93.8                                                      | 575.6 ± 96.9                                                       | 0.24    |
| Median                                 | 637.0                                                             | 627.0                                                               |         |
| Interquartile range                    | 506.0–657.0                                                      | 494.5–653.5                                                        |         |

BMI, body mass index; TIA, transient ischemic attack; APTT, activated partial thromboplastin time; PRU, P2Y12 reaction units; ARU, aspirin reaction units.
### Supplementary Table 2. Test performance characteristics with receiver operating characteristic curve analysis.

|                | AUC   | 95% CI | Sensitivity | Specificity | Cutoff value |
|----------------|-------|--------|-------------|-------------|--------------|
| TEG            |       |        |             |             |              |
| AAI            | 0.62  | 0.48–0.76 | 56.0%      | 76.0%       | > 97.4%      |
| ADPI           | 0.81  | 0.75–0.87 | 68.1%      | 81.8%       | < 58.8%      |
| PL-12          |       |        |             |             |              |
| MAR_{AA}       | 0.54  | 0.42–0.66 | 16%        | 98.0%       | > 49.2%      |
| MAR_{ADP}      | 0.84  | 0.79–0.90 | 95.5%      | 67.7%       | ≥ 28.6%      |

AUC, area under the curve; CI, confidence interval; TEG, thromboelastography; AAI, arachidonic acid inhibition, the percentage inhibition of the contribution from arachidonic acid-stimulated platelets to maximal clot strength (TEG assay); ADPI, ADP inhibition, the percentage inhibition of the contribution from ADP-stimulated platelets to maximal clot strength (TEG assay); MAR_{AA}: maximal platelet aggregation ratio of arachidonic acid-stimulated platelets (PL-12); MAR_{ADP}: maximal platelet aggregation ratio of ADP-stimulated platelets (PL-12).